Clinical Rheumatology最新文献

{"title":"Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters.","authors":"Martin Feuchtenberger, Magdolna Szilvia Kovacs, Axel Nigg, Arne Schäfer","doi":"10.1007/s10067-025-07350-x","DOIUrl":"https://doi.org/10.1007/s10067-025-07350-x","url":null,"abstract":"<p><strong>Introduction /objectives: </strong>International guidelines recommend screening for latent tuberculosis infection (LTBI) and chronic viral hepatitis infections before initiating intensified immunosuppressive therapy. We assessed the prevalence of positive screening tests for LTBI, hepatitis B virus (HBV), and hepatitis C virus (HCV) in patients screened at a large rheumatology outpatient center in Germany.</p><p><strong>Method: </strong>This retrospective cohort study used electronic health records from adult rheumatology patients. The presence of LTBI was evaluated by chest X-rays, patient medical history/self-report, and QuantiFERON®-TB Gold Plus (QFT) interferon-gamma release assays. Antibodies to HBV core antigen (anti-HBc) and HCV were used to assess HBV and HCV, respectively. Statistically significant associations were evaluated by Fisher exact tests.</p><p><strong>Results: </strong>Of 697 screened patients with a rheumatological condition (61.3% female, mean age 60.0 years), 132 (18.9%) patients were positive for LTBI (99 [14.2%]), anti-HBc (39 [5.6%]), or anti-HCV (3 [0.4%]). Nine patients had more than one positive result; different infections were not significantly associated. QFT detected the most LTBI cases (59.5%) followed by patient report/history (42.4%) and chest X-rays (17.2%). Although most patients (83.8%) were positive on only one test, associations among LTBI tests were statistically significant. Biologic disease-modifying antirheumatic drug (bDMARD) use was lower in patients with a positive LTBI screening result compared with all screened patients (73.7% vs 86.4%) and targeted synthetic DMARD (tsDMARD) use was higher (10.1% vs 5.9%).</p><p><strong>Conclusions: </strong>Almost one-fifth of rheumatology patients preparing to initiate intensified immunosuppressive therapy have positive results on screening tests for LTBI or show evidence of exposure to HBV or HCV. These findings support the need for careful screening, even in \"low-prevalence\" countries.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized efficacy and safety evaluation of fulranumab for osteoarthritis.","authors":"Haiyang Kou, Bo Chen","doi":"10.1007/s10067-024-07292-w","DOIUrl":"https://doi.org/10.1007/s10067-024-07292-w","url":null,"abstract":"<p><p>To assess the impact of fulranumab intervention on osteoarthritis (OA) patients and offer a clinically relevant, evidence-based guide for fulranumab intervention in patients with OA. RevMan 5.4 was utilized to conduct a meta-analysis after relevant data on randomized controlled trials of therapeutic interventions for patients with OA were gathered from literature databases such PubMed, Embase, Web of Science, and the Cochrane Library. A total of 8 randomized controlled studies were included, including 1927 patients with osteoarthritis. Meta-analysis showed that compared with the control group, fulranumab intervention had more gains, (MD = - 6.76, 95% CI [- 13.37 to - 0.15]; Z = 2.00; P = 0.05), WOMAC pain (3 mg, week 17) (MD = - 0.78, 95% CI [- 1.10 to - 0.46]; Z = 4.79; P < 0.00001), BPI-SF: pain intensity score (1 mg, week 12) (MD = - 4.29, 95% CI [- 9.15 to 0.57]; Z = 1.73; P = 0.08), and BPI-SF: pain interference (1 mg, week 12) (MD = - 5.98, 95% CI [- 6.64 to - 5.32]; Z = 17.84; P < 0.00001). When used in conjunction with nerve growth factor (NGF) therapy, fulranumab offers an efficient osteoarthritis therapeutic alternative. Patients with osteoarthritis can have a considerable improvement in their WOMAC, short pain inventory, patient global assessment scores, clinical symptoms, and overall quality of life. One possible therapeutic approach for the condition might be to use fulranumab.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing for identifying rare genetic variants related to idiopathic granulomatous mastitis.","authors":"Leyla Ozer, Hande Koksal","doi":"10.1007/s10067-025-07343-w","DOIUrl":"https://doi.org/10.1007/s10067-025-07343-w","url":null,"abstract":"<p><strong>Backgrounds: </strong>To reveal rare genetic factors that cause susceptibility to idiopathic granulomatous mastitis (IGM).</p><p><strong>Methods: </strong>Whole exome sequencing (WES) was performed in 30 patients with histopathologically diagnosed idiopathic granulomatous mastitis. WES analysis mainly focused on 317 genes linked to autoimmunity, autoinflammation, and immune dysregulation.</p><p><strong>Results: </strong>A total of 141 variants were detected in 100 genes. The 40% (12/30) of patients had pathogenic or likely pathogenic variants. The pathogenic/likely pathogenic variants were 10.6% of all variants, and the rest of the variants (89.4%) were classified as VUS. Most of the variants were heterozygous (97.2%) only 4 variants (2.8%) were homozygous. Pathogenic/likely pathogenic variants were detected in FCGR1A, MPO, F5, IL36RN, CLUH, C9, NAXD, PROC, THRB, IFI30, COQ2, RNASEH2B, and SLC29A3 genes. The highest number of variants were detected in UNC13D, VPS13B, EPHB4, NLRP12, TCIRG1, TOM1, IRF9, and PIK3CG.</p><p><strong>Conclusion: </strong>Up to date, our study is the first whole exome sequencing study of IGM patients which aims to find out the rare variants related to etiopathogenesis of the disease. We identified 141 single nucleotide variants of 100 genes, and most of these variants were found in innate immunity-related genes. The current study provides clues for identifying the etiologic factors and designing further functional studies in this rare disease with unknown etiopathogenesis. Key Points •Autoimmunity/autoinflammation-related genetic factors are blamed for etiopathogenesis of idiopathic granulomatous mastitis (IGM). •Mutation in genes related to innate immunity, especially in macrophage functions and phagocytosis, may lead to IGM susceptibility. •Potential candidate genes for genetic susceptibility to IGM may shed light for new treatment options.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of CXCL9, CXCL10, and CXCL13 chemokines in patients with Sjögren's syndrome.","authors":"Selda Hakbilen, Dilek Tezcan, Duygu Eryavuz Onmaz, Sema Yılmaz, Muslu Kazım Körez, Ali Ünlü","doi":"10.1007/s10067-025-07367-2","DOIUrl":"https://doi.org/10.1007/s10067-025-07367-2","url":null,"abstract":"<p><strong>Introduction: </strong>Sjögren's syndrome (SS) is a chronic, systemic, and autoimmune disease characterized by lymphocytic infiltration of all exocrine glands, primarily the lacrimal and salivary glands. Chemokines play a key role in many inflammatory diseases. They play a fundamental role in recruitment, transport, and activation of immune cells. This study aimed to investigate the role of CXCL9, CXCL10, and CXCL13 chemokines in primary SS patients.</p><p><strong>Method: </strong>The study included 62 SS patients and 68 individuals without known systemic or rheumatological disease. CXCL9, CXCL10, and CXCL13 levels were analyzed in both groups using ELISA test kits and compared. The mean age of SS and healthy controls (HC) were similar. White blood cell neutrophil and lymphocyte values were found significantly lower in the SS compared to the HC; ESR value was higher in SS. Other hemogram parameters such as hemoglobin, platelets, monocytes, and CRP did not show a significant difference. CXCL10 levels were found to be significantly higher in SS compared to HC. CXCL13 level was significantly lower in SS. However, there was no statistically significant difference in CXCL9 serum between SS and HC. There was a negative correlation between serum CXCL9 level and lymphocyte and there was also a positive correlation between CXCL13 serum level and leukocyte.</p><p><strong>Conclusion: </strong>CXCL10 chemokine may serve as a potential biomarker for primary SS and it may also be a new therapeutic target. Key Points • Chemokines play a key role in Sjögren's syndrome. • CXCL10 may serve as a potential biomarker for primary SS.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The future of autoimmune disease care: merging genomic insights and imaging for enhanced prognosis in rheumatoid arthritis.","authors":"Akshaya Viswanathan, Neha Brahma, S Vimal","doi":"10.1007/s10067-024-07234-6","DOIUrl":"https://doi.org/10.1007/s10067-024-07234-6","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of miRNAs in the pathogenesis of psoriasis and psoriatic arthritis: a genome-wide Mendelian randomization study.","authors":"Chanxiu Li, Zhanxue Sun","doi":"10.1007/s10067-025-07374-3","DOIUrl":"https://doi.org/10.1007/s10067-025-07374-3","url":null,"abstract":"<p><strong>Background: </strong>MicroRNAs (miRNAs) are critical in the onset and treatment of skin diseases, but the miRNAs causally associated with psoriasis (PSO) and psoriatic arthritis (PsA) remain unclear. This study aims to identify miRNAs with causal associations with PSO and PsA.</p><p><strong>Methods: </strong>Five Mendelian randomization (MR) methods were employed, using miRNA expression quantitative trait loci (mirQTL) data as exposure variables and PSO and PsA as outcome variables. This approach was used to uncover the causal links of miRNAs with both PSO and PsA, with robust sensitivity analyses ensuring the stability of our findings. Finally, miRNet and enrichment analyses were used to predict target genes of the causal miRNAs and their potential biological roles.</p><p><strong>Results: </strong>Our robust findings indicated that miR-27b-3p, miR-204-5p, and miR-6891-3p were notably associated with an enhanced risk of PSO. Additionally, miR-6891-3p was greatly associated with an enhanced risk of PsA. Conversely, miR-29c-3p, miR-181a-3p, miR-181a-5p, miR-181b-5p, and miR-199a-3p were substantially associated with a reduced risk of both PSO and PsA. Enrichment analyses revealed that the target genes of these causal miRNAs were markedly enriched in biological pathways such as apoptosis, Wnt, and PI3K-AKT signaling.</p><p><strong>Conclusion: </strong>This study identifies eight miRNAs causally associated with PSO and five miRNAs associated with PsA, with no observed heterogeneity or pleiotropy. These findings offer potential biomarkers for the diagnosis and treatment of PSO and PsA. Key Points • We conducted the first genome-wide MR study to explore the causal relationships between miRNAs and PSO and PsA. • The study found stable and reliable causal effects of 8 miRNAs on PSO and 5 miRNAs on PsA. • These miRNAs provide important insights into elucidating the pathophysiological mechanisms of PSO and PsA and developing new therapeutic approaches.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of medical comorbidity on HOOS/KOOS/FAOS: a national register-based cohort study of 7850 representative citizens.","authors":"Peter Larsen, Rasmus Elsoe","doi":"10.1007/s10067-025-07372-5","DOIUrl":"https://doi.org/10.1007/s10067-025-07372-5","url":null,"abstract":"<p><strong>Objectives: </strong>Despite extensive validation, the impact of medical comorbidities on the outcomes of the Hip Disability and Osteoarthritis Outcome Score (HOOS), Knee Injury Osteoarthritis Outcome Score (KOOS), and Foot and Ankle Outcome Score (FAOS) remains underexplored. This study aimed to evaluate the effect of medical comorbidities on HOOS, KOOS, and FAOS subscales using a large, nationally representative sample.</p><p><strong>Methods: </strong>This national register-based cohort study invited 26,877 participants to complete HOOS, KOOS, or FAOS questionnaires. Medical comorbidities-including diabetes, chronic obstructive pulmonary disease/asthma, rheumatological diseases, osteoporosis, stroke, obesity, and heart disease-were identified through the Danish National Patient Register.</p><p><strong>Results: </strong>A total of 7850 participants (29%) responded, with 1863 (24%) having medical comorbidities. HOOS/KOOS/FAOS subscale scores were significantly worse in patients with comorbidities, particularly in the Sport/Rec, ADL, and QOL subscales. Mean score differences between participants with and without comorbidities were pain (- 5.7, 95% CI - 6.6 to - 4.7), symptoms (- 4.6, 95% CI - 5.5 to - 3.6), ADL (- 7.1, 95% CI - 8.0 to - 6.1), Sport/Rec (- 10.4, 95% CI - 11.9 to - 8.9), and QOL (- 6.9, 95% CI - 8.2 to - 5.7). Diabetes, rheumatological diseases, and obesity were associated with the greatest complaints.</p><p><strong>Conclusion: </strong>Patients with medical comorbidity reported significantly lower HOOS/KOOS/FAOS subscale scores compared to participants without medical comorbidity. Diabetes, chronic rheumatological diseases, and adiposities were observed with the most complaints. Key Points • Medical comorbidity predicts considerably lower HOOS/KOOS/FAOS subscale scores. • Diabetes, rheumatological diseases, and obesity exerted the most pronounced negative effects on the HOOS/KOOS/FAOS. • Findings underscore the importance of considering comorbidities when interpreting HOOS/KOOS/FOAS subscale scores.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis.","authors":"Ouyang Xie, Meiyu Wu, Andong Li, Kehui Meng, Heng Xiang, Chongqing Tan, Liubao Peng, Yan Ge, Xiaomin Wan","doi":"10.1007/s10067-025-07368-1","DOIUrl":"https://doi.org/10.1007/s10067-025-07368-1","url":null,"abstract":"<p><strong>Objective: </strong>Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, biologics are expensive and the cost-effectiveness of sequential biologic therapy in China remains unknown. The purpose of this study is to evaluate the cost-effectiveness of different sequential treatment option for PsA patients who have not responded to csDMARDs from the perspective of Chinese healthcare system.</p><p><strong>Methods: </strong>We constructed a discrete event simulation model to evaluate the cost-effectiveness of 7 monotherapy treatments and 32 sequential treatments. In sequential therapy, two different types of biologics were used as first-line and second-line treatments, respectively, with the best supportive care (BSC) as the third-line treatment. The primary outcomes included total treatment costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way and probability sensitivity analyses were performed to explore the uncertainty of our model.</p><p><strong>Results: </strong>Compared to all other strategies, initiating with secukinumab followed by etanercept (SEC-ETN) provided the highest health benefits. At a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC-ETN was the most cost-effective strategy, with an ICER of $20,837 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis results confirmed the robust of this conclusion.</p><p><strong>Conclusions: </strong>In China, SEC-ETN may be the most cost-effective strategy for patients who have failed treatment with csDMARDs and have not previously used biologics. The results provide evidence for identifying the optimal biologic treatment strategy for PsA patients in China. Key Points • Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, the cost-effectiveness of sequential biologic therapy in China remains unclear. • At a willingness-to-pay threshold of $38,161, initiating with secukinumab followed by etanercept (SEC-ETN) was cost-effective strategy, outperforming other strategies. • From the perspective of the Chinese healthcare system, the optimal biologic treatment strategy was SEC-ETN in China.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the rheumatology resource gap in Africa.","authors":"Dzifa Dey, Bridget Hodkinson","doi":"10.1007/s10067-025-07362-7","DOIUrl":"https://doi.org/10.1007/s10067-025-07362-7","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of biological products in hip osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Peyman Mirghaderi, Ali Mortezaei, Amin Javidan, Amirhossein Ghaseminejad-Raeini, Behrad Nematollahi","doi":"10.1007/s10067-025-07366-3","DOIUrl":"https://doi.org/10.1007/s10067-025-07366-3","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review aims to evaluate the efficacy and safety of various biological products, such as platelet-rich plasma (PRP), hyaluronic acid (HA), and combination treatments, in alleviating pain and improving function in patients with hip osteoarthritis (OA).</p><p><strong>Methods: </strong>Our review followed the PRISMA guidelines. Literature was searched in PubMed, Scopus, Embase, Web of Science, and CENTRAL Cochrane databases from the beginning until July 2022 hinged upon the previously designed search strings, and citations were downloaded. We included randomized controlled trials (RCTs) involving patients over 18 years old with hip OA, comparing biological products to placebo or other interventions. Data were collected on pain, hip range of motion, functional status, quality of life, and radiological outcomes. Meta-analysis was done on the above-listed outcomes.</p><p><strong>Results: </strong>From 18 RCTs involving 1648 patients, we analyzed the efficacy of various biological products. The mean age of patients was 60.2 years (SD 2.4), and the mean follow-up period was 7.22 months. PRP and HA treatments showed no statistically significant differences in VAS scores in the short-term (SMD = - 0.49, 95% CI, - 1.34-0.36), mid-term (SMD = - 0.25, 95% CI - 1.64-1.15), and long-term (SMD = - 0.22, 95% CI - 1.57-1.12) follow-ups. However, significant differences were found in WOMAC pain short-term (SMD = 0.40, 95% CI - 0.06-0.87), mid-term (SMD = 0.49, 95% CI - 0.85-1.83), and long-term outcomes (SMD = - 0.42, 95% CI - 0.80 to - 0.04). Complications were observed in HA (8%), Hylan G-F (4.9%), and GP-C (50%) groups, while PRP and BCC did not report any complications.</p><p><strong>Conclusion: </strong>Our meta-analysis indicates that biological products, particularly PRP and HA, provide varying degrees of pain relief and functional improvement in hip OA patients, with a generally acceptable safety profile. The significant heterogeneity among studies underscores the need for further research to establish standardized treatment protocols and long-term efficacy.</p><p><strong>Trial registration: </strong>CRD42022312562.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}